The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53
Open accessAbstract
Through targeted homologous recombination, we developed a panel of matched colorectal cancer cell lines that differ only with respect to their endogenous TP53 status. We then used these lines to define the genes whose expression was altered after DNA damage induced by ionizing radiation. Transcriptome analyses revealed a consistent up-regulation of polo-like kinase 1 (PLK1) as well as other genes controlling the G 2 /M transition in the cells whose TP53 genes were inactivated compared with those with WT TP53 genes. This led to the hypothesis that the viability of stressed cells without WT TP53 depended on PLK1 . This hypothesis was validated by demonstrating that stressed cancer cells without WT TP53 alleles were highly sensitive to PLK1 inhibitors, both in vivo and in vitro.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Transactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1145 · Cited by 129
RetractedWAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
Self-citationp53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Self-citationAn Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
Self-citationIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Self-citationMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833
Self-citationRequirement for p53 and p21 to Sustain G 2 Arrest After DNA Damage
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803
Self-citationVousden, K. H., & Lane, D. P. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2147 · Cited by 2,272
WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.
El‐Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Ce, C., Jackman, J., Pietenpol, J. A., Burrell, M., De, H., & Wang, Y. (1994) · PubMed · Cited by 2,078
The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53
Scheffner, M., Huibregtse, J. M., Vierstra, R. D., & Howley, P. M. (1993) · Cell · doi:10.1016/0092-8674(93)90384-3 · Cited by 2,054
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Decision making by p53: life, death and cancer
Oren, M. (2003) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,068
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Principles of Tumor Suppression
Sherr, C. J. (2004) · Cell · doi:10.1016/s0092-8674(03)01075-4 · Cited by 1,034
p53 and Human Cancer: The First Ten Thousand Mutations
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60785-x · Cited by 986
The MDM2 gene amplification database
Momand, J. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.15.3453 · Cited by 982
BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo
Steegmaier, M., Hoffmann, M., Baum, A., Lénárt, P., Petronczki, M., Krššák, M., Gürtler, U., Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.037 · Cited by 834
Regulation ofp53downstream genes
El-Deiry, W. S. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0097 · Cited by 800
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 799
Assessing TP53 status in human tumours to evaluate clinical outcome
Soussi, T., & Béroud, C. (2001) · Nature reviews. Cancer · doi:10.1038/35106009 · Cited by 659
The Small-Molecule Inhibitor BI 2536 Reveals Novel Insights into Mitotic Roles of Polo-like Kinase 1
Lénárt, P., Petronczki, M., Steegmaier, M., Di Fiore, B., Lipp, J. J., Hoffmann, M., Rettig, W. J., Kraut, N., & Peters, J.-M. (2007) · Current Biology · doi:10.1016/j.cub.2006.12.046 · Cited by 653
MDM2 — master regulator of the p53 tumor suppressor protein
Momand, J., Wu, H.-H., & Dasgupta, G. (2000) · Gene · doi:10.1016/s0378-1119(99)00487-4 · Cited by 641
Transcriptional regulation by p53: one protein, many possibilities
Laptenko, O., & Prives, C. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401916 · Cited by 505
UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53
Wang, Q., Fan, S., Eastman, A., Worland, P. J., Sausville, E. A., & O'Connor, P. M. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.14.956 · Cited by 453
Wild-type p53 can down-modulate the activity of various promoters.
Ginsberg, D., Mechta, F., Yaniv, M., & Oren, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.22.9979 · Cited by 435
G2 checkpoint abrogators as anticancer drugs
Kawabe, T. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.513.3.4 · Cited by 377
Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm
Soussi, T., & Wiman, K. G. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.10.001 · Cited by 368
Weinmann, A. S., & Farnham, P. J. (2002) · Methods · doi:10.1016/s1046-2023(02)00006-3 · Cited by 345
Cellular senescence as a tumor-protection mechanism: the essential role of counting
Wright, W. E., & Shay, J. W. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00163-5 · Cited by 306
Nghiem, P., Park, P. K., Kim, Y.-S., Vaziri, C., & Schreiber, S. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161281798 · Cited by 290
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer.
Olivier, M., Hussain, S. P., de Fromentel, C. C., Hainaut, P. L., & Harris, C. C. (2004) · PubMed · Cited by 243
Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
Wang, Y., Li, J., Booher, R. N., Kraker, A. J., Lawrence, T. S., Leopold, W. R., & Sun, Y. (2001) · PubMed · Cited by 210
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 202
Isolation of p53‐target genes and their functional analysis
Nakamura, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03163.x · Cited by 169
Ashwell, S., & Zabludoff, S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5138 · Cited by 163
Mross, K., Frost, A., Steinbild, S., Hedbom, S., Rentschler, J., Kaiser, R., Rouyrre, N., Trommeshauser, D., Hoesl, C. E., & Munzert, G. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.1547 · Cited by 158
Effects of ionizing radiation on cell cycle progression
Bernhard, E. J., Maity, A. M., Muschel, R. J., & McKenna, W. G. (1995) · Radiation and Environmental Biophysics · doi:10.1007/bf01275210 · Cited by 154
Modeling human lung cancer in mice: similarities and shortcomings
Tuveson, D. A., & Jacks, T. (1999) · Oncogene · doi:10.1038/sj.onc.1203107 · Cited by 144
Strategies for therapeutic targeting of the p53 pathway in cancer
Wiman, K. G. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401921 · Cited by 136
Polo and Aurora kinases — lessons derived from chemical biology
Taylor, S. S., & Peters, J. (2008) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2007.11.008 · Cited by 131
Modulation of Gene Expression by Tumor-Derived p53 Mutants
Scian, M. J., Stagliano, K. E., Ellis, M. A., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1568 · Cited by 117
Roberge, M., Berlinck, R. G. S., Xu, L., Anderson, H. J., Lim, L. Y., Curman, D., Stringer, C. M., Friend, S. H., Davies, P., Vincent, I. J., et al. (1998) · PubMed · Cited by 91
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types
Grueneberg, D. A., Degot, S., Pearlberg, J., Li, W., Davies, J. E., Baldwin, A. E., Endege, W. O., Doench, J. G., Sawyer, J., Hu, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808019105 · Cited by 89
Secchiero, P., di Iasio, M. G., Gonelli, A., & Zauli, G. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208785294663 · Cited by 86
Cell Cycle Checkpoint Control Mechanisms That Can Be Disrupted in Cancer
Dash, B. C., & El‐Deiry, W. S. (2004) · Humana Press eBooks · doi:10.1385/1-59259-788-2:099 · Cited by 65
Dose-dependent effects of DNA-damaging agents on p53-mediated cell cycle arrest.
Chang, D., Chen, F., Zhang, F., McKay, B. C., & Ljungman, M. E. (1999) · PubMed · Cited by 55
Potentiation of DNA-Damage-Induced Cytotoxicity by G2Checkpoint Abrogators
Broggini‐Tenzer, A., & Pruschy, M. N. (2003) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011033353533 · Cited by 49
Comparison of the Effect of Mutant and Wild-Type p53 on Global Gene Expression
O’Farrell, T. J., Ghosh, P., Dobashi, N., Sasaki, C. Y., & Longo, D. L. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3639 · Cited by 37
Drug discovery targeting Chk1 and Chk2 kinases.
Zhou, B. S., & Sausville, E. A. (2003) · PubMed · Cited by 36
PLK1 Inhibitors: Setting the Mitotic Death Trap
Plyte, S. E., & Musacchio, A. (2007) · Current Biology · doi:10.1016/j.cub.2007.02.018 · Cited by 35
The P53 Pathway: Targets for the Development of Novel Cancer Therapeutics
Wang, S., & El‐Deiry, W. S. (2006) · Kluwer Academic Publishers eBooks · doi:10.1007/1-4020-7847-1_9 · Cited by 29
Phang, B. H., & Sabapathy, K. (2006) · Oncogene · doi:10.1038/sj.onc.1210112 · Cited by 13
Cellular senescence and cancer
(1999) · doi:10.1002/(sici)1096-9896(199901)187:1
Cited by
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906
Cell cycle proteins as promising targets in cancer therapy
Otto, T., & Sicinski, P. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.138 · Cited by 1,858
High-Resolution CRISPR Screens Reveal Fitness Genes and Genotype-Specific Cancer Liabilities.
Hart, T., Chandrashekhar, M., Aregger, M., Steinhart, Z., Brown, K. R., MacLeod, G., Mis, M., Zimmermann, M., Fradet-Turcotte, A., Sun, S., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.015 · Cited by 1,571
When mutants gain new powers: News from the mutant p53 field
Brosh, R., & Rotter, V. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2693 · Cited by 1,132
Metadata
- Authors
- Sur, S., Pagliarini, R., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-03-10
- Volume
- 106
- Issue
- 10
- Pages
- 3964-3969
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2165582413
- Cited by
- 295
- References
- 59
- FWCI
- 12.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.